A phase II randomized study of chemo-anticoagulation (gemcitabine-dalateparin) [gemcitabine + dalteparin sodium] vs chemotherapy alone (gemcitabine) for locally advanced and metastatic pancreatic adenocarcinoma

Trial Profile

A phase II randomized study of chemo-anticoagulation (gemcitabine-dalateparin) [gemcitabine + dalteparin sodium] vs chemotherapy alone (gemcitabine) for locally advanced and metastatic pancreatic adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2005

At a glance

  • Drugs Dalteparin sodium (Primary)
  • Indications Thromboembolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top